CytRx announced last week that it will advance an siRNA into animal studies as a treatment for type II diabetes and obesity, marking the first time the company has decided to pursue in vivo testing of an RNAi drug candidate.

Separately this week, CytRx President and CEO Steven Kriegsman downplayed the significance of two lawsuits filed against him recently in relation to his one-time directorship of software firm AuthentiDate, stating that the suits have no impact on CytRx.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.